S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
Penny Stock Shows Big Potential (Ad)
These 3 Dividend Growers Yield More Than the 10-Year Note
Closing prices for crude oil, gold and other commodities
Penny Stock Shows Big Potential (Ad)
GameStop Shares Surge On Surprise Profit
Want Diversified Upside in Biotechnology? Check out LABU
Penny Stock Shows Big Potential (Ad)
What is the Consumer Staples Sector?
Nike, Inc’s Q3 Surprise Isn’t All That Surprising: Is It A Buy?
NASDAQ:ABSI

Absci - ABSI Competitors

$1.69
-0.06 (-3.43%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.69
$1.86
50-Day Range
$1.59
$3.41
52-Week Range
$1.53
$9.09
Volume
503,832 shs
Average Volume
487,710 shs
Market Capitalization
$156.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

ABSI vs. DKDCA, NOTV, OABI, MXCT, FSTX, RPHM, CELC, IVVD, ZIMV, and ADCT

Should you be buying Absci stock or one of its competitors? The main competitors of Absci include Data Knights Acquisition (DKDCA), Inotiv (NOTV), OmniAb (OABI), MaxCyte (MXCT), F-star Therapeutics (FSTX), Reneo Pharmaceuticals (RPHM), Celcuity (CELC), Invivyd (IVVD), ZimVie (ZIMV), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector.

Absci vs.

Absci (NASDAQ:ABSI) and Data Knights Acquisition (NASDAQ:DKDCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.

In the previous week, Absci's average media sentiment score of 0.00 equaled Data Knights Acquisition's average media sentiment score.

Company Overall Sentiment
Absci Neutral
Data Knights Acquisition Neutral

Absci has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Data Knights Acquisition has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Absci received 8 more outperform votes than Data Knights Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
AbsciOutperform Votes
8
29.63%
Underperform Votes
19
70.37%
Data Knights AcquisitionN/AN/A

Data Knights Acquisition has a net margin of 0.00% compared to Absci's net margin of -1,960.28%. Data Knights Acquisition's return on equity of 0.00% beat Absci's return on equity.

Company Net Margins Return on Equity Return on Assets
Absci -1,960.28% -33.62% -28.97%
Data Knights Acquisition N/A N/A N/A

Absci currently has a consensus target price of $10.67, suggesting a potential upside of 531.16%. Given Absci's higher possible upside, equities analysts clearly believe Absci is more favorable than Data Knights Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Absci
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Data Knights Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Data Knights Acquisition has lower revenue, but higher earnings than Absci.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Absci$4.78 million32.67-$100.96 million-$1.23-1.37
Data Knights AcquisitionN/AN/A$5.14 millionN/AN/A

47.6% of Absci shares are owned by institutional investors. Comparatively, 78.5% of Data Knights Acquisition shares are owned by institutional investors. 19.4% of Absci shares are owned by company insiders. Comparatively, 23.1% of Data Knights Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Data Knights Acquisition beats Absci on 6 of the 11 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABSI vs. The Competition

MetricAbsciCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$156.14M$3.80B$4.33B$5.81B
Dividend YieldN/A1.17%2.39%4.45%
P/E Ratio-1.3710.5295.6311.70
Price / Sales32.679,590.043,598.8157.70
Price / CashN/A16.2126.8498.19
Price / Book0.4324.634.464.94
Net Income-$100.96M$84.68M$115.42M$190.83M
7 Day Performance0.90%-2.09%-2.47%-1.39%
1 Month Performance-27.47%-14.51%-6.55%-6.86%
1 Year Performance-77.56%-38.34%-16.10%-18.39%

Absci Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DKDCA
Data Knights Acquisition
0 of 5 stars
$10.65
flat
N/AN/A$159.32MN/A0.002,021Upcoming Earnings
NOTV
Inotiv
2.3406 of 5 stars
$4.61
-1.9%
$17.33
+276.0%
-80.5%$118.15M$547.66M-0.352,204
OABI
OmniAb
1.7077 of 5 stars
$3.33
-7.2%
$10.29
+208.9%
N/A$382.35MN/A0.00N/AUpcoming Earnings
News Coverage
MXCT
MaxCyte
2.4448 of 5 stars
$4.13
-5.7%
$9.00
+117.9%
-40.1%$424.77M$44.26M-17.9684Analyst Revision
FSTX
F-star Therapeutics
0 of 5 stars
$7.12
flat
N/A+86.4%$156.50M$21.17M-3.9184
RPHM
Reneo Pharmaceuticals
2.0385 of 5 stars
$6.42
+3.9%
$23.67
+268.6%
+81.4%$157.48MN/A-3.2324Gap Up
CELC
Celcuity
1.2631 of 5 stars
$10.01
-2.4%
$20.00
+99.8%
+22.2%$154.76MN/A-4.1739
IVVD
Invivyd
1.6681 of 5 stars
$1.42
-9.6%
$2.00
+40.8%
N/A$154.75MN/A-0.55N/A
ZIMV
ZimVie
2.5411 of 5 stars
$6.07
-4.0%
$12.50
+105.9%
-74.8%$159.28M$913.86M-2.492,700
ADCT
ADC Therapeutics
1.9361 of 5 stars
$1.99
-3.9%
$10.17
+410.9%
-85.8%$152.85M$209.91M-0.99312
This page (NASDAQ:ABSI) was last updated on 3/23/2023 by MarketBeat.com Staff